Back to Treatments

Treatment

Dapagliflozin (SGLT2 Inhibitor)

1
Conditions
50
Trials
50K
Participants
65%
Average Safety

Condition Evidence

Chronic kidney disease due to glomerulonephritis

50 trials · 50K participants

82% effectiveness · 65% safety
Dapagliflozin (SGLT2 Inhibitor) | DFDA